News
Zepbound vs. Wegovy: A Weight-Loss Drug Showdown
Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent trial. The study enhances Lilly's position in the obesity drug market, highlighting Zepbound's effectiveness compared to Wegovy,
Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...
Novo Nordisk A/S trimmed its forecasts as sales of the drugmaker’s blockbuster obesity and diabetes medicines struggle with ...
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...
Novo Nordisk stock slumped early Monday as the drugmaker was facing a hit to revenue from several different directions. This ...
Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases.
Wegovy can cause some side effects. The most common side effects of semaglutide are nausea, vomiting, and diarrhoea. Other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback